凯时治疗下肢动脉硬化闭塞症的临床研究  

Clinical study of Lipo PGE1 on the treatment of lower limb artherosclerosis

作　　者：张云峰[1] 王海东[1] 管强[1] 刘增庆[1] 

机构地区：[1]山西省人民医院,山西太原030012

出　　处：《中外医疗》2013年第2期67-67,69,共2页China & Foreign Medical Treatment

摘　　要：目的探讨前列腺素E1脂微球载体制剂(LipoPGE1,凯时)治疗下肢动脉硬化闭塞症疗效及安全性。方法 190例动脉硬化闭塞症患者随机分为治疗组100例和对照组90例。对照组给予PGE1粉针剂;治疗组给予凯时注射液静脉滴注。疗程均为30d。治疗前后分别检测主观症状及体征、间歇性跛行距离、踝肱指数(ABI)等变化。结果两组ABI治疗后与治疗前比较,以及两组间治疗后比较,差异有统计学意义(P<0.05)。治疗组的总有效率与对照组比较,差异有统计学意义(P<0.05)。凯时的不良反应少而轻微。结论凯时注射液治疗动脉硬化闭塞症效果显著,安全性好。Objective To observe the therapeutic and safety of prostaglandin E1 fat microspheres carrier preparations （Lipo PGE1） in the treatment of lower limb artherosclerosis（ASO）. Methods 190 cases of lower limb artherosclerosis patients were randomly divided into two groups： treatment group of 100 cases and control group of 90 cases. The control group used PGE1-CD;The treatment group used Lipo PGE1, ivdrip injection treatment based on the control group. The treatment course of two groups for 30 days .Before and after the treatment to monitor changes in indicators of subjective symptoms and signs respectively,intermittent claudi- cators, ankle- brachial index distance （ABI）,（etc）. Results In the ABI indication,after treatment compared with those before treatment and the comparison between the two groups after treatment the differences are significant （P〈0.05）. The total effective rate of the treatment group compared with controls, the differences are significant （P〈0.05）. The adverse reactions of Lipo PGE1 slightly less. Conclusion The results of Lipo PGE1 injection treatment of lower limb artherosclerosis, security in good.

关 键 词：前列腺素E1脂微球载体制剂 动脉硬化闭塞症 

分 类 号：R97[医药卫生—药品]